CIS
TEVA icon

Capital International Sarl’s Teva Pharmaceuticals TEVA Stock Holding History

Capital International Sarl’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-315,588
Closed -$2.79M – 232
2023
Q1 		$2.79M Buy
315,588
+44,066
+16% +$436K 0.14% 153
2022
Q4 		$2.48M Buy
271,522
+87,507
+48% +$764K 0.17% 139
2022
Q3 		$1.49M Buy
+184,015
New +$1.63M 0.12% 165
2022
Q1 		– Sell
-23,286
Closed -$187K – 275
2021
Q4 		$187K Hold
23,286
– – 0.01% 257
2021
Q3 		$227K Sell
23,286
-29,228
-56% -$274K 0.02% 236
2021
Q2 		$520K Sell
52,514
-13,564
-21% -$144K 0.04% 209
2021
Q1 		$763K Sell
66,078
-17,749
-21% -$204K 0.07% 182
2020
Q4 		$809K Buy
83,827
+22,757
+37% +$218K 0.08% 178
2020
Q3 		$550K Buy
61,070
+10,121
+20% +$107K 0.07% 180
2020
Q2 		$628K Buy
50,949
+38,749
+318% +$438K 0.08% 158
2020
Q1 		$110K Buy
+12,200
New +$125K 0.02% 196

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital International Sarl's TEVA Position: Q2 2023 in Review

Capital International Sarl sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 315,588 shares — an estimated $2.79M sold.

Capital International Sarl first reported a position in TEVA in Q1 2020 and held it in 11 quarters. The position peaked at $2.79M in Q1 2023. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Capital International Sarl reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Capital International Sarl sold 315,588 Teva Pharmaceuticals shares in Q2 2023, an estimated $2.79M.
  • Capital International Sarl first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 11 quarters.
  • Capital International Sarl's Teva Pharmaceuticals position peaked at $2.79M in Q1 2023.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Capital International Sarl's 13F filing for Q2 2023, filed 11 Aug 2023.